Compounds > torcetrapib
Page last updated: 2024-09-04

torcetrapib and Apolipoprotein B-100, Familial Defective

torcetrapib has been researched along with Apolipoprotein B-100, Familial Defective in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Catalano, G; Chapman, MJ; Fournier, N; Frisdal, E; Guerin, M; Julia, Z; Le Goff, W; Vedie, B1
Bots, ML; Dogan, S; Duivenvoorden, R; Evans, GW; Grobbee, DE; Kastelein, JJ; Shear, CL; Visseren, FL1
Barter, PJ; Bots, ML; Burgess, L; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Kuivenhoven, JA; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI1
Bots, ML; Evans, GW; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI1
El Harchaoui, K; Kastelein, JJ; Stroes, ES; van der Steeg, WA1
Chapman, MJ; Duchene, E; Guerin, M; Julia, Z; Le Goff, W; Nguyen, T; Shear, CL; Thuren, T1

Reviews

1 review(s) available for torcetrapib and Apolipoprotein B-100, Familial Defective

ArticleYear
The role of CETP inhibition in dyslipidemia.
    Current atherosclerosis reports, 2007, Volume: 9, Issue:2

    Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Dyslipidemias; Esters; Female; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Male; Quinolines; Sulfhydryl Compounds

2007

Trials

5 trial(s) available for torcetrapib and Apolipoprotein B-100, Familial Defective

ArticleYear
Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:2

    Topics: Adult; Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL2; Lipoproteins, HDL3; Liver; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pyrroles; Quinolines; Scavenger Receptors, Class B; Time Factors; Treatment Outcome

2009
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.
    Annals of medicine, 2010, Volume: 42, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Internal; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reproducibility of Results; Tunica Intima; Ultrasonography

2010
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
    The New England journal of medicine, 2007, Apr-19, Volume: 356, Issue:16

    Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines

2007
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
    Current medical research and opinion, 2007, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Aged; Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Research Design; Tunica Intima; Ultrasonography

2007
Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.
    Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:1

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Chylomicrons; Dietary Fats; Dietary Proteins; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Male; Middle Aged; Postprandial Period; Pyrroles; Quinolines

2008